Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | PPIA | P62937 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | GLP1R | P43220 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5901336 | 0.86 | PPIA (0.47) | PPIANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4663183 | 0.85 | MCHR1 (0.48) | MCHR1NPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4662918 | 0.79 | MCHR1 (0.51) | MCHR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL5901225 | 0.79 | CA12 (0.45) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5901935 | 0.77 | HPGD (0.51) | PPIANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4403626 | 0.75 | SMN1; SMN2 (0.61) | PPIANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL16056780 | 0.73 | MRGPRX4 (0.47) | PPIANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4279981 | 0.73 | HSD17B10 (0.61) | PPIANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL28633934 | 0.73 | KDM4E (0.56) | PPIANPC1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL340393 | 0.72 | SMN1; SMN2 (0.72) | NPC1HPGDRAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
| EP-1575924-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA Pharma AG (DE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004054984-A1 | 4-SUBSTITUTED BENZIMIDAZOLES AND THEIR USE AS INHIBITORS OF GASTRIC SECRETION | ALTANA PHARMA AG (DE) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194969-A1 | 4-Substituted benzimidazoles and their uses as inhibitors of gastric secretion | GIPR, VIP, SI | MCHR1 2432/4885PPIA 3266/4885NPC1 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.